Press Releases LianBio

Equities

LIAN.Y

US53000N1081

Market Closed - OTC Markets Other stock markets 03:59:31 2024-05-28 pm EDT			5-day change	1st Jan Change
0.3137 ^USD	-5.51%		+0.16%	-92.98%

May. 10	China's Zeekr prices US IPO at top of range to raise $441 million	RE
May. 07	Geely's EV Unit Zeekr Targets Up to $367.5 Million From NYSE IPO	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

LianBio Announces Voluntarily Delisting from Nasdaq	Feb. 28	AQ
LianBio Announces Completion of Strategic Review	Feb. 13	AQ
LianBio Enters into Agreement Assigning its Rights for NBTXR3 in China and Other Asian Markets	Dec. 26	AQ
LianBio Announces Departure of Chief Financial Officer	Dec. 20	AQ
LianBio Announces Departure of Chief Executive Officer	Dec. 19	AQ
LianBio’s Board of Directors Unanimously Determines not to Pursue Unsolicited Proposal from Concentra Biosciences	Dec. 06	AQ
LianBio Confirms Receipt of Unsolicited Proposal from Concentra Biosciences	Dec. 01	AQ
LianBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update	Nov. 13	AQ
LianBio Announces Topline Results from Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis	23-10-30	AQ
LianBio Announces Presentation of Data from Phase 2a Study of Infigratinib in Patients with Gastric Cancer at ESMO Congress 2023	23-10-25	AQ
LianBio Enters into Agreement with Bristol Myers Squibb for Mavacamten in China and Other Asian Markets	23-10-24	AQ
LianBio Announces Results from Phase 3 EXPLORER-CN Trial of Mavacamten Presented at the European Society of Cardiology Congress and Simultaneous Publication in JAMA Cardiology	23-08-28	AQ
LianBio Reports Second Quarter 2023 Financial Results and Provides Corporate Update	23-08-14	AQ
LianBio Announces First Patient Treated in Phase 1 Trial of SHP2 Inhibitor BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations	23-08-03	AQ
LianBio Partner Tarsus Pharmaceuticals Announces U.S. FDA Approval of XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the Treatment of Demodex Blepharitis	23-07-26	AQ
LianBio Partner NANOBIOTIX Enters into License Agreement with Janssen for Radioenhancer NBTXR3, with LianBio Retaining Development and Commercialization Rights in Greater China, South Korea, Singapore and Thailand	23-07-18	AQ
LianBio Announces Phase 3 EXPLORER-CN Data Accepted for Late-Breaking Presentation at the European Society of Cardiology Congress 2023	23-07-17	AQ
LianBio Announces Clinical Supply Agreement with AstraZeneca in China to Evaluate BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations	23-07-12	AQ
LianBio Announces Marketing Approval of CAMZYOS® (mavacamten) in Singapore	23-06-26	AQ
LianBio Completes Enrollment in Pivotal Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis	23-06-08	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases LianBio

Equities

LIAN.Y

US53000N1081

Press Releases

Filters